| 1 | Investment in one of the Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility | ₹107.00 Cr |
| 2 | Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company | ₹73.48 Cr |
| 3 | Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries | ₹20.22 Cr |
| 4 | Funding the working capital requirements of the Company | ₹43.26 Cr |
| 5 | Investment in the Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements | ₹59.48 Cr |
| 6 | Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes | ₹154.37 Cr |
